Doxorubicin adjuvants to reduce toxicity and methods for using the same
US9468613B2 · kind B2 · utility
0Cited by
17References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2015 |
| Grant date | Oct 18, 2016 |
| Priority date | — |
| Expiry date | May 20, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.